To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLS)

Aga, Evgenia

Badal-Faesen, Sharlaa

Bartlett, John A.

Crump, John A.

Hosseinipour, Mina C.

Kallungal, Beatrice A.

Katzenstein, David A.

Klingman, Karin L.

Kumarasamy, Nagalingeswaran

Norton, Michael R.

Ribaudo, Heather J.

Stevens, Wendy S.

Supparatpinyo, Khuanchai

Wallis, Carole L.

AIDS

PubMed

Carolina Digital Repository

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

OBJECTIVE: To evaluate virologic response rates of lopinavir/ritonavir (LPV/r) monotherapy as second-line antiretroviral treatment (ART) among adults in resource-limited settings (RLSs). DESIGN: An open-label pilot study of LPV/r monotherapy in participants on first-line nonnucleoside reverse transcriptase inhibitor three-drug combination ART with plasma HIV-1 RNA 1000-200 000  copies/ml. METHODS: Participants were recruited from five sites in Africa and Asia within the AIDS Clinical Trials Group (ACTG) network. All participants received LPV/r 400/100  mg twice daily. The primary endpoint was remaining on LPV/r monotherapy without virologic failure at week 24. Participants with virologic failure were offered addition of emtricitabine and tenofovir (FTC/TDF) to LPV/r. RESULTS: Mutations associated with drug resistance were encountered in nearly all individuals screened for the study. One hundred and twenty-three participants were enrolled, and 122 completed 24 weeks on study. A high proportion remained on LPV/r monotherapy without virologic failure at 24 weeks (87%). Archived samples with HIV-1 RNA levels less than 400  copies/ml at week 24 (n=102) underwent ultrasensitive assay. Of these individuals, 62 had levels less than 40  copies/ml and 30 had levels 40-200  copies/ml. Fifteen individuals experienced virologic failure, among whom 11 had resistance assessed and two had emergent protease inhibitor mutations. Thirteen individuals with virologic failure added FTC/TDF and one individual added FTC/TDF without virologic failure. At study week 48, 11 of 14 adding FTC/TDF had HIV-1 RNA levels less than 400  copies/ml. CONCLUSION: In this pilot study conducted in diverse RLS, LPV/r monotherapy as second-line ART demonstrated promising activity

Bartlett, JA

Ribaudo, HJ

Wallis, CL

Aga, E

Katzenstein, DA

Stevens, WS

Norton, MR

Klingman, KL

Hosseinipour, MC

Crump, John Andrew

Supparatpinyo, K

Badal-Faesen, S

Kallungal, BA

Kumarasamy, N

DukeSpace

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

http://dx.doi.org/10.1097/QAD.0b013e328353b066

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

Abstract

Similar works

Full text

Available Versions

Carolina Digital Repository

DukeSpace